High‐affinity urokinase‐derived cyclic peptides inhibiting urokinase/urokinase receptor‐interaction: effects on tumor growth and spread
Authors:
- Viktor MagdolenVMViktor Magdolen
- 4 September 2002
- journal article
- Published by Wiley in FEBS Letters
- Vol. 528 (1-3) , 212-216
Abstract
Urokinase‐type plasminogen activator (uPA) binds with high affinity to its specific cell surface receptor (uPAR) (CD87) via a well‐defined sequence within the N‐terminal region of uPA (uPA19–31). Since this uPA/uPAR‐interaction plays a significant role in tumor cell invasion and metastasis, it has become an attractive therapeutic target. Two small peptidic cyclic competitive antagonists of uPA/uPAR‐interaction have been developed, based on the uPAR binding site in uPA: WX‐360 (cyclo21,29[D‐Cys21]‐uPA21–30[S21C;H29C]) and its norleucine (Nle) derivative WX‐360‐Nle (cyclo21,29[D‐Cys21]‐uPA21–30[S21C;K23Nle;H29C]). These peptides display an only five to 10‐fold lower affinity to uPAR as compared to the naturally occurring uPAR‐ligand uPA. In this study, WX‐360 and WX‐360‐Nle were tested in nude mice for their potency to inhibit tumor growth and intraperitoneal spread of lacZ‐tagged human ovarian cancer cells. Intraperitoneal administration of either cyclic peptide (20 mg peptide/kg; 1× daily for 37 days) into the tumor‐bearing nude mice resulted in a significant reduction of tumor weight and spread within the peritoneum as compared to the untreated control group. This is the first report demonstrating effective reduction of tumor growth and spread of human ovarian cancer cells in vivo by small synthetic uPA‐derived cyclic peptides competitively interfering with uPA/uPAR‐interaction. Thus, both WX‐360 and WX‐360‐Nle are promising novel compounds to reduce dissemination of human ovarian carcinoma.Keywords
This publication has 24 references indexed in Scilit:
- Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapyBiochemical Society Transactions, 2002
- Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumoursExpert Opinion on Biological Therapy, 2001
- Cyclo19,31[D-Cys19]-uPA19-31 Is a Potent Competitive Antagonist of the Interaction of Urokinase-Type Plasminogen Activator with Its Receptor (CD87)Biological Chemistry, 2001
- A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivoThe FASEB Journal, 2000
- The urokinase plasminogen activator system as a novel target for tumour therapyFibrinolysis and Proteolysis, 2000
- Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)Cancer Gene Therapy, 2000
- The plasminogen activation system in tumor growth, invasion, and metastasisCellular and Molecular Life Sciences, 2000
- High-affinity urokinase receptor antagonists identified with bacteriophage peptide display.Proceedings of the National Academy of Sciences, 1994
- Scattered micrometastases visualized at the single‐cell level: Detection and re‐isolation of lacZ‐labeled metastasized lymphoma cellsInternational Journal of Cancer, 1994
- Prevention of metastasis by inhibition of the urokinase receptor.Proceedings of the National Academy of Sciences, 1993